| Issue |
Section |
Title |
File |
| Vol 84, No 2 (2012) |
Editorial article |
Impairment of intestinal mucosa composition in mechanisms of intestinal dysfunction development in patients with hepatic cirrhosis |
|
| Vol 88, No 2 (2016) |
Editorial article |
Current principles in the screening, diagnosis, and therapy of colorectal cancer |
(Rus)
|
| Vol 88, No 8 (2016) |
Editorial article |
Long-term infliximab therapy for ulcerative colitis in real clinical practice |
(Rus)
|
| Vol 89, No 2 (2017) |
Editorial article |
Efficacy of adalimumab for Crohn’s disease in real clinical practice |
(Rus)
|
| Vol 90, No 3 (2018) |
Editorial article |
Stem Cell Therapy for Perianal Crohn’s Disease |
(Rus)
|
| Vol 90, No 6 (2018) |
Editorial article |
Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice |
(Rus)
|
| Vol 90, No 2 (2018) |
Editorial article |
Personalized medicine in the treatment of inflammatory bowel diseases |
(Rus)
|
| Vol 90, No 2 (2018) |
Editorial article |
Mesenchymal stromal cells of bone marrow and azathioprine in Crohn's disease therapy |
(Rus)
|
| Vol 90, No 12 (2018) |
Editorial article |
Adherence to therapy of patients with inflammatory bowel diseases |
(Rus)
|
| Vol 90, No 11 (2018) |
Editorial article |
Clostridium difficile in inflammatory bowel disease |
(Rus)
|
| Vol 91, No 4 (2019) |
Editorial article |
O.V. Knyazev, A.V. Kagramanova, I.A. Korneeva, K.K. Noskova, S.V. Belousov, A.I. Parfenov |
(Rus)
|
| Vol 91, No 8 (2019) |
Editorial article |
Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation |
(Rus)
|
